| Title: |
Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization |
| Authors: |
Fuchs, Anke; Gliwiński, Mateusz; Grageda, Nathali; Spiering, Rachel; Abbas, Abul, K; Appel, Silke; Bacchetta, Rosa; Battaglia, Manuela; Berglund, David; Blazar, Bruce; Bluestone, Jeffrey, A.; Bornhäuser, Martin; ten Brinke, Anja; Brusko, Todd, M; Cools, Nathalie; Cuturi, Maria, Cristina; Geissler, Edward; Giannoukakis, Nick; Gołab, Karolina; Hafler, David, A; Marieke van Ham, S; Hester, Joanna; Hippen, Keli; Di Ianni, Mauro; Ilic, Natasa; Isaacs, John; Issa, Fadi; Iwaszkiewicz-Grześ, Dorota; Jaeckel, Elmar; Joosten, Irma; Klatzmann, David; Koenen, Hans; van Kooten, Cees; Korsgren, Olle; Kretschmer, Karsten; Levings, Megan; Marek-Trzonkowska, Natalia, Maria; Martinez-Llordella, Marc; Miljkovic, Djordje; Mills, Kingston, H G; Miranda, Joana, P; Piccirillo, Ciriaco, A; Putnam, Amy, L; Ritter, Thomas; Roncarolo, Maria, Grazia; Sakaguchi, Shimon; Sánchez-Ramón, Silvia; Sawitzki, Birgit; Sofronic-Milosavljevic, Ljiljana; Sykes, Megan; Tang, Qizhi; Vives-Pi, Marta; Waldmann, Herman; Witkowski, Piotr; Wood, Kathryn; Gregori, Silvia; Hilkens, Catharien, M U; Lombardi, Giovanna; Lord, Phillip; Martinez-Caceres, Eva, M; Trzonkowski, Piotr |
| Contributors: |
CRTD-DFG Research Center for Regenerative Therapies Dresden Dresden, Germany (Medical Faculty); Technische Universität Dresden = Dresden University of Technology (TU Dresden); Medical University of Gdańsk; King‘s College London; Newcastle University Newcastle; University of California San Francisco (UC San Francisco); University of California (UC); University of Bergen (UiB); Stanford School of Medicine Stanford; Stanford Medicine; Stanford University-Stanford University; IRCCS Ospedale San Raffaele Milan, Italy; Uppsala University; University of Minnesota Twin Cities (UMN); University of Minnesota System (UMN); Universiteit van Amsterdam = University of Amsterdam (UvA); University of Florida Gainesville (UF); Universiteit Antwerpen = University of Antwerp; Antwerp University Hospital Edegem (UZA); Dendritic cells and immunoregulation in transplantation and immunopathology (Team 1 - U1064 Inserm - CRTI); Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE); Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE); Université de Nantes (UN)-Université de Nantes (UN); University Hospital Regensburg; Carnegie Mellon University Pittsburgh (CMU); University of Chicago; Yale School of Medicine New Haven, Connecticut (YSM); University of Oxford; University of Chieti-Pescara; University of Belgrade Belgrade; NHS Foundation Trust London; The Royal Marsden NHS Foundation Trust London; Medizinische Hochschule Hannover = Hannover Medical School (MHH); Radboud University Medical Center Nijmegen (RadboudUMC); Immunologie - Immunopathologie - Immunothérapie CHU Pitié Salpêtrière (I3); CHU Charles Foix AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU); Leiden University Medical Center Leiden (LUMC); Universiteit Leiden = Leiden University; Uppsala University Hospital; Göteborgs Universitet = University of Gothenburg (GU); Helmholtz Zentrum München = German Research Center for Environmental Health (HMGU); BC Children's Hospital Research Institute Vancouver, BC, Canada (BCCHR); University of British Columbia Canada (UBC); Trinity College Dublin; Universidade de Lisboa = University of Lisbon = Université de Lisbonne Lisboa (ULISBOA); McGill University = Université McGill Montréal, Canada; National University of Ireland Galway (NUI Galway); Stanford University; The University of Osaka (UOsaka); Department of Clinical Immunology, Hospital Clínico San Carlos; Universidad Complutense de Madrid = Complutense University of Madrid Madrid (UCM); Charité - UniversitätsMedizin = Berlin University Medicine; Columbia University New York; Institut d’Investigació Germans Trias i Pujol = Germans Trias i Pujol Research Institute (IGTP); The University of Chicago Medicine Chicago; Universitat Autònoma de Barcelona = Autonomous University of Barcelona = Universidad Autónoma de Barcelona (UAB); This work was supported by a grant from the European Cooperation in Science and Technology (COST) for the AFACTT project (Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies; BM1305). COST is part of the EU Framework Programme Horizon 2020.; European Project: COST |
| Source: |
ISSN: 1664-3224. |
| Publisher Information: |
CCSD; Frontiers |
| Publication Year: |
2018 |
| Collection: |
Université de Nantes: HAL-UNIV-NANTES |
| Subject Terms: |
T regulatory cells; cell therapy; good manufacturing practice; immune tolerance; minimum information model; immunotherapy; [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology |
| Description: |
International audience ; Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treatment for the variety of autoimmune and allergic diseases as well as posttransplant complications. Nevertheless, current manufacturing of Tregs as a cellular medicinal product varies between different laboratories, which in turn hampers precise comparisons of the results between the studies performed. While the number of clinical trials testing Tregs is already substantial, it seems to be crucial to provide some standardized characteristics of Treg products in order to minimize the problem. We have previously developed reporting guidelines called minimum information about tolerogenic antigen-presenting cells, which allows the comparison between different preparations of tolerance-inducing antigen-presenting cells. Having this experience, here we describe another minimum information about Tregs (MITREG). It is important to note that MITREG does not dictate how investigators should generate or characterize Tregs, but it does require investigators to report their Treg data in a consistent and transparent manner. We hope this will, therefore, be a useful tool facilitating standardized reporting on the manufacturing of Tregs, either for research purposes or for clinical application. This way MITREG might also be an important step toward more standardized and reproducible testing of the Tregs preparations in clinical applications. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/29379498; PUBMED: 29379498 |
| DOI: |
10.3389/fimmu.2017.01844 |
| Availability: |
https://inserm.hal.science/inserm-02157859; https://inserm.hal.science/inserm-02157859v1/document; https://inserm.hal.science/inserm-02157859v1/file/fimmu-08-01844.pdf; https://doi.org/10.3389/fimmu.2017.01844 |
| Rights: |
https://about.hal.science/hal-authorisation-v1/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.3DAC4853 |
| Database: |
BASE |